SCHEMBL14133395

SCHEMBL14133395

CC(=O)N1N=C(c2ccc(NS(C)(=O)=O)cc2)CC1c1cccc(F)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.74
▸ PKM P14618 7/20 0.74
▸ KDM4E B2RXH2 6/20 0.74
▸ MEN1 O00255 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ MAPT P10636 2/20 0.62
▸ CA1 P00915 1/20 0.60
▸ CA2 P00918 1/20 0.60
▸ CA4 P22748 1/20 0.60
▸ CA9 Q16790 1/20 0.60
▸ NT5E P21589 1/20 0.60
▸ LMNA P02545 1/20 0.59
▸ BCL2 P10415 3/20 0.59
▸ BECN1 Q14457 3/20 0.59
▸ GLA P06280 2/20 0.59
▸ HTT P42858 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ PTGS2 P35354 1/20 0.58
▸ POLB P06746 1/20 0.57
▸ MAOA P21397 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133539 0.90 ALDH1A1 (0.75) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133805 0.89 KDM4E (0.71) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133441 0.89 KDM4E (0.71) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133320 0.89 KDM4E (0.71) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133875 0.88 PTGS2 (0.74) ALDH1A1PKMKDM4EMAPTCA1
SCHEMBL14136329 0.87 KDM4E (0.74) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133743 0.87 KDM4E (0.80) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133905 0.87 KDM4E (0.68) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133394 0.87 KDM4E (0.68) ALDH1A1PKMKDM4EMEN1KMT2A
SCHEMBL14133342 0.86 ALDH1A1 (0.57) ALDH1A1PKMKDM4EMAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 ALDH1A1 2476/4885PKM 5/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback